Communiqué from EXTRAordinary General Meeting in Prostatype Genomics AB (publ) held on 7 december 2023

Prostatype Genomics AB (publ), listed on the Nasdaq First North Growth Market, held an extraordinary general meeting today on 7 December 2023, whereby the following decisions were unanimously made.

The extraordinary general meeting resolved to approve the board of directors’ resolution on 7 November 2023 to increase Prostatype Genomics share capital with a maximum of SEK 16,724,400.98 (the new quota value –SEK 0.01 – after the proposed reduction is applied) of which not more than SEK 11,946,000.70 refers to an increase due to an issue of shares, and not more than SEK 4,778,400.28 refers to an increase due to an issue of warrants) through an issue of a maximum of 119,460,007 so-called units with preferential rights for existing shareholders.

Each unit consists of ten (10) shares and four (4) warrants of series TO3. This means that a maximum of 1,194,600,070 new shares and a maximum of 477,840,028 new warrants can be issued. The right to subscribe for units shall with preferential rights belong to those who, on the record date for the rights issue – 11 December 2023 – are recorded as shareholders of the Company, where one (1) existing share shall entitle to one (1) unit right.

The record date for participation in the rights issue shall be 11 December 2023. Subscription of units based on unit rights shall be made by simultaneous cash payment during the period from and including 13 December 2023 to and including 27 December 2023. The board shall have the right to extend the subscription and payment period. Subscription of units without subscription rights shall be made on a separate subscription list during the same period, from and including 13 December 2023 to and including 27 December 2023. Payment for units that are subscribed without subscription rights shall be made by cash payment according to instruction on contract note, however not later than five (5) banking days from receipt of the contract note. The board shall have the right to extend the subscription and payment period. The units are issued at a subscription price of SEK 0.40 per unit, which corresponds to a subscription price of SEK 0.04 per share. The warrants are issued free of charge. If all units are subscribed and paid for, the Company will receive a total of SEK 47,784,002.80 before transaction costs (to avoid any misunderstanding: any liquidity for the subscription of warrants is not included in this amount).

Each (1) warrant of series TO3 shall entitle to subscription of one (1) new share in the Company at a subscription price corresponding to 70 percent of the average volume-weighted share price of the Company’s share during the period from 5 April 2024 up to and including 19 April 2024, however, not less than the shares then current quota value. Subscription of shares with warrants of series TO3 shall take place during the period from 22 April 2024 up to and including 3 May 2024. The terms and conditions that shall apply for the warrants are attached in a separate document.

In order to enable the implementation of the aforementioned share issue, the meeting also approved the board's proposal to change the articles of association by increasing the interval for number of shares. Further, in order obtain a more suitable share capital for the company and to enable the implementation of the share issue, the general meeting resolved on a reduction of the Company’s share capital by SEK 5,973,000.35. The reduction amount shall be allocated as non-restricted equity. This means that the share capital will be reduced from SEK 7,167,600.42 to SEK 1,194,600.07. As a result, the nominal value of the Company’s share will be reduced from SEK 0.06 per share to SEK 0.01 per share. The resolution on the rights issue implies that the share capital will be increased to the same extent as the reduction of the share capital.

The general meeting resolved on election of Jörgen Dahlström as member of the board and that the board, for the time until the end of the next annual general meeting, therefore should consist of Anders Lundberg, Michael Häggman, Håkan Englund, Mattias Prage and Jörgen Dahlström.

At the general meeting, outgoing board member Henrik Nilsson was thanked for his time in the board.

For further information, please contact:
Fredrik Persson, CEO for Prostatype Genomics

Tel: +46 (0) 73 049 77 01, e-mail: [email protected]